Informationen:
Fehler:
ID
26017
Beschreibung
Enzastaurin in Combination of Capecitabine to Treat Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00437294
Link
https://clinicaltrials.gov/show/NCT00437294
Stichworte
Versionen (2)
- 02.10.17 02.10.17 -
- 04.10.17 04.10.17 -
Rechteinhaber
See clinicaltrials.gov
Hochgeladen am
4. Oktober 2017
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Breast Cancer NCT00437294
Eligibility Breast Cancer NCT00437294
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Breast Cancer NCT00437294
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Secondary malignant neoplasm of female breast | Breast cancer recurrent
Item
have been diagnosed with metastatic or recurrent breast cancer.
boolean
C0346993 (UMLS CUI [1])
C0278493 (UMLS CUI [2])
C0278493 (UMLS CUI [2])
Anthracyclines | Taxane
Item
have been previously treated with both an anthracycline and a taxane.
boolean
C0282564 (UMLS CUI [1])
C0215136 (UMLS CUI [2])
C0215136 (UMLS CUI [2])
Chemotherapy Regimen Quantity
Item
have not received more than two prior chemotherapy treatment programs.
boolean
C0392920 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,2])
Antineoplastic Hormonal Agents Discontinued
Item
have stopped any antitumoral hormonal treatment before you enroll in this study.
boolean
C0282559 (UMLS CUI [1,1])
C1444662 (UMLS CUI [1,2])
C1444662 (UMLS CUI [1,2])
Menstruation Serum pregnancy test negative | Childbearing Potential Serum pregnancy test negative | Menstruation Contraceptive methods | Childbearing Potential Contraceptive methods
Item
have a negative pregnancy blood test if menstruating or capable of becoming pregnant. you must use an approved birth control method during the study and for 3 months after stopping study treatment.
boolean
C0025344 (UMLS CUI [1,1])
C0430061 (UMLS CUI [1,2])
C3831118 (UMLS CUI [2,1])
C0430061 (UMLS CUI [2,2])
C0025344 (UMLS CUI [3,1])
C0700589 (UMLS CUI [3,2])
C3831118 (UMLS CUI [4,1])
C0700589 (UMLS CUI [4,2])
C0430061 (UMLS CUI [1,2])
C3831118 (UMLS CUI [2,1])
C0430061 (UMLS CUI [2,2])
C0025344 (UMLS CUI [3,1])
C0700589 (UMLS CUI [3,2])
C3831118 (UMLS CUI [4,1])
C0700589 (UMLS CUI [4,2])
Protocol Compliance Unable | Lacking Able to swallow Tablets
Item
cannot follow the study procedures (for example, you can not swallow tablets)
boolean
C0525058 (UMLS CUI [1,1])
C1299582 (UMLS CUI [1,2])
C0332268 (UMLS CUI [2,1])
C2712086 (UMLS CUI [2,2])
C0039225 (UMLS CUI [2,3])
C1299582 (UMLS CUI [1,2])
C0332268 (UMLS CUI [2,1])
C2712086 (UMLS CUI [2,2])
C0039225 (UMLS CUI [2,3])
Cancer treatment
Item
are receiving another treatment for your cancer.
boolean
C0920425 (UMLS CUI [1])
Investigational New Drugs
Item
have received another experimental drug in the last 4 weeks.
boolean
C0013230 (UMLS CUI [1])
Heart Disease
Item
have had serious heart disease within last 6 months.
boolean
C0018799 (UMLS CUI [1])
Pregnancy | Breast Feeding
Item
are pregnant or breast-feeding.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])